Ignite Creation Date:
2024-05-06 @ 1:39 PM
Last Modification Date:
2024-10-26 @ 1:17 PM
Study NCT ID:
NCT04084951
Status:
COMPLETED
Last Update Posted:
2023-04-14
First Post:
2019-09-01
Brief Title:
Study of SQZ-PBMC-HPV in Patients With HPV16 Recurrent Locally Advanced or Metastatic Solid Tumors
Sponsor:
SQZ Biotechnologies
Organization:
SQZ Biotechnologies
Study Overview
Official Title:
A Phase 1 Multicenter Open-Label Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A02 Patients With HPV16 Recurrent Locally Advanced or Metastatic Solid Tumors
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 1 open-label multicenter study of the safety and tolerability immunogenic effects antitumor activity and pharmacodynamics of SQZ-PBMC-HPV as monotherapy and in combination with atezolizumab or other immune checkpoint inhibitors in HLA-A02 patients with recurrent locally advanced or metastatic human papillomavirus strain 16 positive HPV16 solid tumors The study includes patients with anal rectal cervical head and neck penile vulvar or vaginal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None